Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MRTX1719 · 1 trial · 6 indications
| Arm | Type | Description |
|---|---|---|
| Phase 1/1B | EXPERIMENTAL | Dose Escalation/Evaluation |
| Phase 1b Sub-studies 1-4 | EXPERIMENTAL | - |
| Phase 1b Sub-study 5 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| MRTX1719 | DRUG | MRTX1719 is a potent PRMT5-MTA inhibitor. Specified dose on specified days |
Inclusion Criteria * Histologically confirmed diagnosis of a solid tumor malignancy with homozygous deletion of the MTAP gene detected in tumor tissue. * Unresectable or metastatic disease. * Presence of a tumor lesion amenable to mandatory biopsy for pharmacodynamic evaluation at baseline and on-s...
MRTX1719 is an investigational small molecule being studied for the treatment of mesothelioma and other solid tumors, including non-small cell lung cancer, malignant peripheral nerve sheath tumors, pancreatic adenocarcinoma, and advanced solid tumors. It is currently in Phase 1 clinical development.
MRTX1719 targets PRMT5, a protein involved in cellular processes. It is being studied in solid tumors with MTAP deletion, as this genetic alteration may make tumors more susceptible to PRMT5 inhibition.
MRTX1719 is being developed by Bristol-Myers Squibb Company, a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol BMY.
MRTX1719 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 study is currently recruiting participants to evaluate its safety and efficacy.
MRTX1719 is being evaluated in a Phase 1 study with the identifier NCT05245500, titled 'Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion.' The trial is recruiting participants in the United States and aims to enroll approximately 336 patients.
MRTX1719 is a distinct investigational compound and is not known to be the same as any other marketed drug. It is being studied under its own name in clinical trials for solid tumors with MTAP deletion.